SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Saliva Diagnostics (SALV) -- Ignore unavailable to you. Want to Upgrade?


To: Steven Seefeldt who wrote (2085)2/16/1998 5:09:00 PM
From: rl  Read Replies (2) | Respond to of 3369
 
I don't know exactly what you mean by "pump and dump." I'll assume it has to do with buying in and hyping a stock long enough for it to go up and profitable sales can occur. That is not the case in the SALV transaction. Scenarios that have happened in the past go like this; offshore buyer acquires large chunks of stock in US company through foreign vehicle (usually these individuals are US citizens, but have placed money in fronts in Swiss and other accounts); stock is bought at a discount to trading price (in the range of 20-50%); historically, the stock could not be sold for 41 days, now 1 year; these Reg S transactions began not passing the SEC smell test, so the format changed to Reg D Convertible Debenture deals; the buyer (sic, investor) covered his money primarily by the knowledge that he would be selling large blocks in the near future and the stock price would fall. They bet on the downturn and establish a short position based on a formula developed for these types of transactions; the investors have large blocks at a discount to cover their short sell. Ask yourself, why does SALV trade such large volumes? Trace the conversion dates of the last financing and you can see the obvious trend. I would expect that the last "investor", Tailwind is out of SALV stock now. I would also guess that they didn't lose a penny. If you know any management at small publicly traded companies, ask them how many times per day they are asked to do these types of financings. They are almost like boiler room operations. The stock never goes up with the company receiving the money until the investors have sold their stock.
I am ambivalent. I know exactly what SALV has done and I don't know if they had any alternative. I am just attempting to make people see that this transaction is not going to raise the stock price of SALV. Just the opposite. It will keep the firm functioning. Maybe with enough time and new management, they'll make it. But expect the stock to fall even lower than it is. I'm assuming that the reverse will pass. The stock will have a difficult time staying above $1.oo for long because of the selling pressure that will come from the "investors." This financing will not enable SDS to even think of beginning a $3-5 million FDA effort. One practical demand of the FDA is that you have the comittment and finances to complete trials if you are allowed to conduct them. SDS may have one, but not the other.